Specific niche view of the structured sector hierarchy. Useful for precedent work where broader sector slices include too much noise.
| Target | Buyer / Investor | Sector | Geo | Transaction size | EV / EBITDA |
|---|---|---|---|---|---|
| Organon | Sun Pharmaceutical Industries Limited | Biopharmaceuticals | $12,000M – $16,200M | 9× – 12× | |
| Entegris’ Life Sciences Fluid Management business | Savillex, Thompson Street Capital Partners | Biopharmaceuticals | $91.0M – $123M | 8× – 11× | |
| NewBridge Pharmaceuticals | DKSH | Biopharmaceuticals | $390M | 8× – 11× | |
| BrevisRefero | Life Science Connect, Latticework Capital | Biopharmaceuticals | $9.3M – $12.6M | 6× – 8× | |
| PolyPeptide Group AG | Samsung Biologics Co., Ltd., Samsung Peptide AG | Biopharmaceuticals | $676M – $914M | 11× – 15× | |
| Crinetics Pharmaceuticals | Vertex Pharmaceuticals | Biopharmaceuticals | $10,000M | n/m | |
| Carolina Components Group | Sheridan Capital Partners | Biopharmaceuticals | $66.0M – $89.0M | 8× – 11× | |
| Clinical Best Solutions | Penta Hospitals Badania Kliniczne | Biopharmaceuticals | $9.2M – $12.4M | 6× – 8× | |
| AmbioPharm | CordenPharma, Astorg | Biopharmaceuticals | $245M – $330M | 12× – 16× | |
| mAbxience Holding S.L. | Fresenius SE & Co. KGaA | Biopharmaceuticals | $795M | 10× – 13× |
Bins are observed deal frequencies across disclosed transactions. Use as a directional reference, not a target valuation.
Use the directory on the recent deals hub to switch between countries, sectors and sub-sectors. A free account unlocks the structured filters that go beyond the public view.